Autres langues Akeso, Inc.

Actions

9926

KYG0146B1032

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:15 18/04/2024			Varia. 5j.	Varia. 1 janv.
45,4 ^HKD	-2,89 %		-6,87 %	-2,16 %

22/03	Akeso va lever plus d'un milliard de dollars HK par le biais d'une vente d'actions	MT
19/03	Akeso enregistre son tout premier bénéfice en 2023 ; dépasse les prévisions de BPA	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	25/03
Akeso to Raise Over HK$1 Billion Via Share Sale	22/03
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast	19/03
Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC	06/03
Akeso Books First-Ever Profit in 2023; Shares Fall 5%	05/03
Akeso, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	05/03
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16/02
Summit Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Call on February 20, 2024	15/02
Akeso Unit Buys 35% Stake in Biopharmaceutical Firm from Dawnrays; Akeso Shares Slide 3%	09/02
Summit Therapeutics to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference	08/02
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023	08/02
Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI	23/01
Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap	08/01
Akeso, Inc. Announces Innovative Clinical Development Roadmap	08/01
Chinese Medical Regulator Accepts Akeso’s Supplemental New Drug Application for Gastric Cancer Therapy	05/01
Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer	05/01
Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naive Acute Myeloid Leukemia at ASH 2023	18/12
Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023	15/12
Akeso Publishes Results from Three Investigator-Initiated Trials	05/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Akeso, Inc.

Actions

9926

KYG0146B1032

Autres langues

Filtres